Monoclonal antibodies for the treatment of Ebola virus disease

References

• World Health Organization. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271–293.
   PubMed Web of Science ®Google Scholar
• Centers of Disease Control and Prevention (CDC). Outbreaks Chronology: Ebola virus disease. [cited 2015 Nov 11]. Available from: http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html
   Google Scholar
• Saez AM, Weiss S, Nowak K, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2014;7:17–23.
   PubMed Web of Science ®Google Scholar
• WHO Ebola response team. Ebola virus disease in West Africa - The first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481–1495.
   PubMed Web of Science ®Google Scholar
• WHO situation report – 28 April 2016. [cited 2016 May 22]. Available from: http://www.who.int/csr/disease/ebola/situation-reports/archive/en/
   Google Scholar
• Negredo A, Palacios G, Vázquez-Morón S, et al. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog. 2011;7;e1002304.
   PubMed Web of Science ®Google Scholar
• Kiley MP, Bowen ET, Eddy GA, et al. Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirol. 1982;18:24–32.
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Becker S, Ebihara H, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155:2083–2103.
   PubMed Web of Science ®Google Scholar
• Bharat TA, Noda T, Riches JD, et al. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci USA. 2012;109:4275–4280.
   PubMed Web of Science ®Google Scholar
• Beniac DR, Melito PL, Devarennes SL, et al. The organisation of ebola virus reveals a capacity for extensive, modular polyploidy. PLoS ONE. 2012;7:e29608.
   PubMed Web of Science ®Google Scholar
• Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nature Rev Microbiol. 2015;13:663–676.
   PubMed Web of Science ®Google Scholar
• Mehedi M, Falzarano D, Seebach J, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011;85:5406–5414.
   PubMed Web of Science ®Google Scholar
• Murin CD, Fusco ML, Bornholdt ZA, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci USA. 2014;111:17182–17187.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849–862.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Bioterrorism agents/diseases. [cited 2016 Apr 29]. Available from: http://emergency.cdc.gov/agent/agentlist.asp#e
   Google Scholar
• Grobusch MP, Visser BJ, Boersma J, et al. Ebola virus disease: Basics the medical specialist should know. Neth J Crit Care. 2015;22:6–14.
   Google Scholar
• World Health Organization. Ebola vaccines, therapies, and diagnostics - Questions and Answers. [cited 2016 Apr 29]. Available from: http://www.who.int/medicines/emp_ebola_q_as/en/
   Google Scholar
• Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647–1660.
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus ebola vaccine – preliminary report. N Engl J Med. 2015 Apr 1. [Epub ahead of print]. DOI: 10.1056/NEJMoa1414216
   PubMedGoogle Scholar
• Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA. N Engl J Med. 2016;374:1635–1646.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–866.
   PubMed Web of Science ®Google Scholar
• Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines. 2015;3:125–138.
   PubMedGoogle Scholar
• Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.
   PubMed Web of Science ®Google Scholar
• Dunning J, Sahr F, Rojek A, et al. Experimental treatment of ebola virus disease with TKM-130803: A single-arm phase 2 clinical trial. PLoS Med. 2016;13:e1001997.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Lee ACH, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896–1905.
   PubMed Web of Science ®Google Scholar
• Kreil TR. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerging Infect Dis. 2015;21:521–523.
   PubMed Web of Science ®Google Scholar
• Van Griensven J, De Weiggheleire A, Delamou A, et al. The use of ebola convalescent plasma to treat ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis. 2016;62:69–74.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Whaley KJ, Olinger GG, et al. Antibody therapeutics for Ebola virus disease. Curr Opin Virol. 2016;17:45–49.
   PubMed Web of Science ®Google Scholar
• González-González E, Alvarez MM, Márquez-Ipiña AR, et al. Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Crit Rev Biotechnol. 2015;26:1–16.
   Google Scholar
• Corti D, Misasi J, Mulangu S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351:1339–1342.
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287:1664–1666.
   PubMed Web of Science ®Google Scholar
• Davidson E, Bryan C, Fong RH, et al. Mechanism of binding to ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol. 2015;89:10982–10992.
   PubMed Web of Science ®Google Scholar
• Qiu X, Alimonti JB, Melito PL, et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol. 2011;141:218–227.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53.
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Lv M, et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med. 2016;8:329–333.
   Web of Science ®Google Scholar
• Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Science; 2001.
   Google Scholar
• Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012;109:18030–18035.
   PubMed Web of Science ®Google Scholar
• Pettitt J, Zeitlin L, Kim do H, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5:199ra113.
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4:138ra81.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Fernando L, et al. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med. 2013;5:207ra143.
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep. 2013;3:3365.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Nicastri E, Lanini S, et al. Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infect Dis. 2015;15:432.
   PubMed Web of Science ®Google Scholar
• Schibler M, Vetter P, Cherpillod P, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis. 2015;15:1034–1040.
   PubMed Web of Science ®Google Scholar
• Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402–2409.
   PubMed Web of Science ®Google Scholar
• Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol. 2010;11:1723–1728.
   Web of Science ®Google Scholar
• Chippaux JP. Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis. 2014;20:44.
   PubMed Web of Science ®Google Scholar
• Pigott DM, Golding N, Mylne A, et al. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg. 2015;109:366–378.
   PubMed Web of Science ®Google Scholar
• Furuyama W, Marzi A, Nanbo A, et al. Discovery of an antibody for pan-ebolavirus therapy. Sci Rep. 2016;6:20514.
   PubMed Web of Science ®Google Scholar
• Flyak AI, Shen X, Murin CD, et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell. 2016;164:392–405.
   PubMed Web of Science ®Google Scholar
• Holtsberg FW, Shulenin S, Vu H, et al. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against ebola and Sudan viruses. J Virol. 2015;90:266–278.
   PubMed Web of Science ®Google Scholar
• Flyak AI, Ilinykh PA, Murin CD, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell. 2015;160:893–903.
   PubMed Web of Science ®Google Scholar
• Keck ZY, Enterlein SG, Howell KA, et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2015;90:279–291.
   PubMed Web of Science ®Google Scholar
• Wong G, Qiu X, Olinger GG, et al. Post-exposure therapy of filovirus infections. Trends Microbiol. 2014;22:456–463.
   PubMed Web of Science ®Google Scholar